Walley T, Murphy M, Codd M, Johnston Z, Quirke T
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
Pharmacoepidemiol Drug Saf. 2000 Dec;9(7):591-8. doi: 10.1002/pds.544.
In an attempt to curb the rapidly rising costs of primary care prescribing in Ireland, the government introduced a financial incentive scheme in 1993, to encourage general practitioners to restrain their prescribing.
To investigate the effects of a financial incentive scheme on GP prescribing in Ireland on prescribing costs and volume, and on some specific therapeutic areas.
Prescribing for 3 years before (1990-1992) and 3 years (1993-1995) after the introduction of incentives, based on a defined cohort of 233 general practitioners in the area of one health board. GPs were divided into tertiles based on their performance against their prescribing budgets into 'savers' (generally underspent and received incentive payments), modest overspenders and large overspenders.
Savers were always lower cost prescribers than the other groups. They contained their rate and costs of prescribing in contrast to the other groups, e.g. percentage rise in prescribing costs in the year after the introduction of the scheme -7.9%, +1.2% and +7.3% respectively, (P < 0.05) for savers, modest overspenders and large overspenders respectively. This effect was short lived however and was gone by the third year of the study.
The financial incentives had a marked effect on prescribing volume and cost on some practices who could achieve targets and hence incentive payments. The incentives had little effect on high spending practices. Such incentive schemes need careful evaluation if they are not to become perverse to the good health of patients.
为抑制爱尔兰初级医疗处方费用的迅速上涨,政府于1993年推出了一项经济激励计划,以鼓励全科医生限制其处方量。
调查爱尔兰一项经济激励计划对全科医生处方量、处方费用以及某些特定治疗领域的影响。
以一个健康委员会辖区内233名全科医生组成的特定队列人群为基础,记录引入激励措施前3年(1990 - 1992年)和引入后3年(1993 - 1995年)的处方情况。根据全科医生相对于其处方预算的表现,将他们分为三个等级:“节省者”(通常支出低于预算并获得激励付款)、适度超支者和大量超支者。
“节省者”的处方费用始终低于其他组。与其他组相比,他们控制了处方率和费用,例如,在该计划实施后的第一年,“节省者”、适度超支者和大量超支者的处方费用增长率分别为 -7.9%、+1.2% 和 +7.3%,(P < 0.05)。然而,这种效果是短暂的,在研究的第三年就消失了。
经济激励措施对一些能够实现目标从而获得激励付款的医疗机构的处方量和费用产生了显著影响。激励措施对高支出医疗机构影响不大。如果此类激励计划不想对患者的健康造成不良影响,就需要仔细评估。